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The identification of genetic causes for Mendelian disorders has been based on the collection of multi-incident families, linkage analysis,
and sequencing of genes in candidate intervals. This study describes the application of next-generation sequencing technologies to
a Swiss kindred presenting with autosomal-dominant, late-onset Parkinson disease (PD). The family has tremor-predominant dopa-
responsive parkinsonism with a mean onset of 50.65 7.3 years. Exome analysis suggests that an aspartic-acid-to-asparagine mutation
within vacuolar protein sorting 35 (VPS35 c.1858G>A; p.Asp620Asn) is the genetic determinant of disease. VPS35 is a central compo-
nent of the retromer cargo-recognition complex, is critical for endosome-trans-golgi trafficking and membrane-protein recycling, and is
evolutionarily highly conserved. VPS35 c.1858G>A was found in all affected members of the Swiss kindred and in three more families
and one patient with sporadic PD, but it was not observed in 3,309 controls. Further sequencing of familial affected probands revealed
only one other missense variant, VPS35 c.946C>T; (p.Pro316Ser), in a pedigree with one unaffected and two affected carriers, and thus
the pathogenicity of this mutation remains uncertain. Retromer-mediated sorting and transport is best characterized for acid hydrolase
receptors. However, the complex has many types of cargo and is involved in a diverse array of biologic pathways from developmental
Wnt signaling to lysosome biogenesis. Our study implicates disruption of VPS35 and retromer-mediated trans-membrane protein
sorting, rescue, and recycling in the neurodegenerative process leading to PD.Parkinson disease (PD [MIM 168600]) affects 1% of indi-
viduals older than 65 years. Patients develop both motor
and nonmotor symptoms and suffer an inexorable decline
in function. Dopaminergic therapies provide temporary
relief but are not without side-effects and do not slow
disease progression.1 About 14% of patients with PD report
one or more first-degree relatives with parkinsonism.2
Studies of familial parkinsonism have identified patho-
genic mutations in several genes, and such identifications
have provided mechanistic insight and novel targets for
therapeutic intervention.3 These loci have been associated
with idiopathic PD, emphasizing the importance of
studying monogenic forms of disease (see the PDGene
database in the Web Resources and Nalls et al.4).
All Mendelian forms of parkinsonism have been identi-
fied through classic linkage and Sanger sequence anal-
ysis.3 This study describes NGS applied to a multi-incident
Swiss family with autosomal-dominant, late-onset PD (CH;
Figure 1). The clinical features of this kindred, which
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16 unaffected individuals excluded point mutations and
copy-number variants (CNVs) in genes previously impli-
cated in monogenic parkinsonism.5
To identify the novel pathogenic mutation causing PD
in this Swiss kindred, we performed exome sequencing
analysis in an affected pair of first-degree cousins (Figure 1).
The capture of exonic regions and the subsequent
sequencing and characterization of variants was performed
by Knome, Inc. NimbleGen Sequence Capture Arrays were
used for isolating the genomic coding regions to be
sequenced. The NimbleGen Arrays, which contain 2.1
million probes that capture ~180,000 exons and ~550
miRNA, were used for interrogation of genomic regions
from CH III-2 and III-13. Sequencing was subsequently
performed on an Illumina Genome Analyzer by 76 bp
paired-end reads. The mean coverage per targeted base
was 51.6-fold for III-2 and 43.8-fold for III-13, and 73.2%
and 60.7% of bases, respectively, had R20-fold coverage.
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Figure 1. Pedigrees with VPS35 Muta-
tions
Individual pedigrees are labeled and
numbered according to their geographic
origin (CH, Switzerland; US, United States;
TN, Tunisia; YE, Yemenite Jews from
Israel). An asterisk indicates an inferred
mutation carrier. Filled symbols indicate
affected individuals, and the correspond-
ing age at disease onset is indicated; na,
not available. Heterozygote mutation
carriers (M) and wild-type (wt) genotypes
are indicated.
(A) Original family used for exome
sequencing and identification of VPS35
p.Asp620Asn.
(B) Additional kindreds presenting VPS35
p.Asp620Asn mutations.
(C) Pedigree presenting the p.Pro316Ser
variant.97.0% for III-2 and III-13, respectively. Adaptor sequences
from reads were filtered via a local dynamic programming
algorithm. Reads with more than 12 bp of overlap with
adaptor sequences were deemed contaminated and
removed; only those reads of 30 bp or longer were used
for further analysis. Reads with more than six missing
bases or 40 consecutive identical bases were omitted
from further processing. The remaining sequences were
aligned to a reference sequence (Hg18, build 36.1) with
SOAPaligner (parameters -a -D -o -r 1 -t -c -f 4), followed
by SOAPsnp so that consensus and call genotypes (param-
eters -i -d -o -r 0.00005 -e 0.0001 -M -t -u -L -s 2 -T) could
be assembled. Validation of common SNP genotypes was
conducted against dbSNP v129. Structural variations were
determined by the paired-end method and clustering algo-
rithm alignment against CNVs in the Database of Genomic
Variants v6 (November 2008). This analysis identifiedThe American Journal of Humana total of 34,754 and 29,952 variants
for III-2 and III-13, respectively.
Assuming these two family members
have the same genetic cause of disease
reduced the number of variants to
17,872 common to both individuals.
On the basis of the genotypes of eight
publicly available HapMap samples,6
additional polymorphisms were
excluded, leaving 4,256 novel vari-
ants. After variants on the X chro-
mosome and homozygous changes
(autosomal-dominant inheritance of
disease was assumed), noncoding
variants, synonymous changes, and
variants present in dbSNP v130 were
excluded, only 69 variants remained.
We recognize that next-generation
capture and sequencing methods are
limited in coverage and that some
bioinformatics results might be erro-neous. Thus, we used Sanger sequencing of these novel
variants in one sample used for NGS (III-2), two additional
affected family members (III-6 and III-9), and one unaf-
fected spouse (II-2) to assess the accuracy of NGS genotype
calls and segregation with disease. Thirty-six variants were
an artifact; they could not be confirmed by Sanger
sequencing and appeared to be a consequence of mis-
aligned repeat sequences. Thirty-three variants were vali-
dated, and six were present in family members with PD
but not observed in the spouse (Table S1). Only two
variants, c.3035C>T (p.Ala1012Val) in integrin alpha X
(ITGAX; RefSeq accession number NM_000887.3 [MIM
151510]) and c.1858G>A (p.Asp620Asn) in vacuolar
protein sorting 35 ortholog (VPS35; RefSeq accession
number NM_018206.4 [MIM 601501]), were not observed
in 184 randomly selected US control subjects of European
descent. Both variants are on the same chromosomalGenetics 89, 162–167, July 15, 2011 163
Figure 2. VPS35 Mutations and Cross-species Conservation
Protein orthologs were aligned via ClustalW. Amino acid positions for VPS35 p.Pro316Ser and p.Asp620Asn are highlighted in black.
Protein orthologs with amino acid positions differing from those of the human sequence are indicated in gray. RefSeq accession
numbers: Homo sapiens, NP_060676.2; Pan troglodytes, XP_001161439.1; Mus musculus, NP_075373.1; Rattus norvegicus, XP_214646.3;
Bos taurus, NP_001039723.1; Canis familiaris, XP_532570.2; Gallus gallus, NP_001005842.1; Xenopus laevis, NP_001089981.1; Danio
rerio, NP_001020688.2; Drosophila melanogaster, NP_726175.3; and Saccharomyces cerevisiae, NP_012381.1. An asterisk indicates that
five aminoacids have been excluded from Drosophila melanogaster and Saccharomyces cerevisiae at this position.region 16p12.1-q12.1 haplotype and were found in all
affected family members and one unaffected family
member (III-3; Figure 1). Additional support for variants
in chromosomal region 16p12.1-q12.1 is provided by
linkage data (Figure S1).
Both variants were subsequently genotyped in a multi-
ethnic case-control series consisting of 4,326 patients and
3,309 controls. This series comprises eight independent
PD series from the US, Canada, Norway, Poland, Ireland,
Tunisia, Taiwan, and Israel (Yemenite Jews). The demo-
graphics for eachseries arepresented inTableS2.Allpatients
were examined and observed longitudinally by a move-
ment-disorders neurologist and diagnosed with PD accord-
ing to published criteria.7 Patients andunrelated controls of
identical ethnicity but without evidence of neurological
disease were consecutively selected. The ethical review
boards at each institutionapproved the study, andall partic-
ipantsprovided informedconsent.A combinationof Seque-
nomMassArray iPLEX (San Diego, CA) and TaqMan probes
was used for genotyping, and all mutations were confirmed
by direct sequencing. Four patients (three familial and one
sporadic) and no controls were identified as having VPS35
p.Asp620Asn; in those three families, a total of nine affected
individuals are present and carry themutation (Figure 1). In
contrast, the ITGAX p.Ala1012Val mutation was found in
one control (61 years) and one familial case (42 years at
onset), butnoother sampleswere available to allow segrega-
tion to be examined. Carrier frequencies for both variants
are provided in Table S3. This data indicate that VPS35
p.Asp620Asn is a pathogenic mutation, whereas ITGAX
p.Ala1012Val is a rare variant. VPS35 is highly conserved
from humans to yeast, supporting the pathogenicity of
the p.Asp620Asn substitution (Figure 2), whereas ITGAX is
not evolutionarily conserved. Additionally, p.Asp620Asn
is an acidic-to-basic change and is predicted to be a delete-
rious substitution (SIFT score ¼ 0), whereas p.Ala1012Val
is not (SIFT score ¼ 0.16).
Haplotype analysis of VPS35 p.Asp620Asn was per-
formed with microsatellite markers between D16S401164 The American Journal of Human Genetics 89, 162–167, July 15, 2and D16S3044 (Table 1). One primer of each pair was
labeled with a fluorescent tag; sequences for novel markers
are provided in Table S4. Polymerase chain reactions
(PCRs) were performed under standard conditions, and
products were run on an ABI 3730 genetic analyzer. Results
were analyzed with GeneMapper 4.0 software (Applied
Biosystems). Genotyping of VPS35 kindreds shows that
the p.Asp620Asn substitution is a mutational hotspot; it
has arisen independently from at least four separate
mutational events (Table 1). Only two haplotypes (CH
and YE-2) share alleles for an adjacent microsatellite
marker (Chr16_45.333M). Interestingly, p.Asp620Asn in
two families that share similar ethnicity does not appear
to be identical by descent (YE-1 and YE-2).
The average age at disease onset for the CH kindred is
50.6 5 7.3 years (range 42–64 years) and is comparable
to 48.3 5 8.6 years (range 40–64 years), the mean age of
onset for other families affected by VPS35 p.Asp620Asn.
However, the mutation has incomplete, age-associated
penetrance; among these pedigrees, there are four unaf-
fectedmutation carriers whowere between 49 and 67 years
at the time of exam (data not shown).
In an attempt to identify novel mutations, we sequenced
all 17 VPS35 exons in 190 multiethnic familial probands
from the US, Canada, Norway, Poland, Ireland, Tunisia,
Taiwan, Israel (Yemenite Jews), France, Switzerland, and
Sweden. The ethical review boards at each institution
approved the study, and all participants provided informed
consent. Primer pairs used for sequencing VPS35 exons
and exon-intron boundaries by PCR are provided in
Table S4. PCR products were purified from unincorporated
nucleotides via Agencourt bead technology (Beverly, MA)
with Biomek FX automation (Beckman Coulter, Fullerton,
CA). Sequence analysis was performed as previously
described.8 Sequencing of 106 US probands identified
two novel variants, one silent (c.945A>T; p.Gly315Gly)
and one missense (c.946C>T; p.Pro316Ser). The age at
disease onset for the patients with these variants was 65
and 52 years, respectively. In 22 Tunisian probands, one011
Table 1. 16p12.1-q12.1 Haplotypes of Kindreds with the VPS35 p.Asp620Asn Mutation
Positiona cMb CH YE-2 YE-1 TN US-1
D16S401 24,593,458 46.94 172 172 172 176 172/174
D16S3068 25,468,102 48.53 139 141/147 143 147 141
D16S753 31,180,950 57.79 260 264 272 264 264/268
Chr16_45.023M 45,023,561 - 295 295 295 293 295
VPS35 p.Asp620Asn 45,253,865 - A A A A A
Chr16_45.333M 45,333,651 - 294 294 292 288 278
D16S3105 45,349,601 58.46 187 187 187 193 191
Chr16_45.615M 45,615,739 - 147 147 149 149 149
Chr16_45.806M 45,806,285 - 246 242 246 246 246
Chr16_45.835M 45,835,953 - 235 243 237 237 235
Chr16_45.855M 45,855,831 - 212 206 210/212 210 210
D16S3044 45,995,037 58.46 197 193 195 191 191/195
Microsatellite allele sizes are given in base pairs, consistent with Centre d’E´tude du Polymorphisme Humain (CEPH) standards (Table S4). Haplotypes that are
possibly shared between CH and YE-2 kindreds are italicized. For markers with an unknown phase, both alleles are given.
a Markers are shown with their physical locations (NCBI Build 36.1).
b Sex-averaged centimorgan positions are given from the Marshfield Comprehensive Human Genetic Map when available.additional variant (c.2210C>T; p.Ala737Val) was identi-
fied in one patient with disease onset at 60 years.
Sequencing of VPS35 in ethnically matched controls
(94 US, 47 Tunisian) identified p.Gly315Gly in one US
control and p.Ala737Val in one Tunisian control. The
presence of these two variants in their corresponding
ethnically matched controls suggests they are nonpatho-
genic polymorphisms. No additional variants, including
p.Pro316Ser, were identified in these control samples or
in probands from other populations.
Two additional family members from the VPS35
p.Pro316Ser kindred were available (US-2, Figure 1), and
both subjects were carriers; one was diagnosed with PD
at 54 years, and the other displayed hand tremor and
micrographia at 67 years but did not fulfill the clinical
criteria for PD. To further discern the pathogenicity of
this variant, we genotyped c.946C>T (p.Pro316Ser) in
a multi-ethnic case-control series consisting of 4,326
patients and 3,309 controls (Table S2). One Norwegian
control subject (86 years) with themutation was identified.
Thus, the genetic evidence for the pathogenicity of
p.Pro316Ser is inconclusive. However, the high level of
species conservation suggests an important functional
role (Figure 2). Additional studies are required if we are to
determine whether p.Pro316Ser is a pathogenic mutation,
a risk factor, or a neutral polymorphism.
We also evaluated VPS35 CNVs as a cause of disease in
the 190 familial probands previously described. We used
two genomic probes against exon 6 and exon 15 of
VPS35 and two endogenous control assays against exon 5
of PSEN2 [MIM 600759] and exon 5 of SNCA [MIM
162890] to identify whole-gene CNVs. All primers and
probes were purchased from Applied Biosystems, andThe Amsequences are available on request. Quantitative PCR was
carried out with the TaqMan expression chemistry pro-
tocol, 25 ng genomic DNA was amplified with 0.25 ml
primer probe and 2.5 ml TaqMan 23 Universal PCR Master
Mix (Applied Biosystems). The thermal cycle conditions
inclued 50C for 2 min, 95C for 10 min, and then 40
cycles at 95C for 15 s for denaturation and 60C for
1 min for annealing and extension. All assays were per-
formed in quadruplicate on the ABI 7900HT Fast Real-
Time PCR System and analyzed with ABI SDS 2.2.2 Soft-
ware (Applied Biosystems). This analysis did not identify
CNVs in VPS35.
Genes linked to familial parkinsonism have highlighted
loci associated with idiopathic PD. Using published
genome-wide association study (GWAS) datasets,9–11 we
examined evidence for disease association with VPS35
observed no such evidence (p values ¼ 0.1–0.9; Table S5).
Nevertheless, coverage of VPS35 was limited, and a lack
of association should not preclude more detailed study in
ethnically diverse populations.
VPS35 is a critical component of the retromer cargo-
recognition complex, which is involved in the recycling
of membrane proteins between endosomes and the trans-
Golgi network.12,13 In mammals the pentameric assembly
includes the recognition complex of VPS35, VPS29 [MIM
606932], and either VPS26A [MIM 605506] or VPS26B
[MIM 610027], as well as sorting nexins (one of each of
the following pairs: SNX1 [MIM 601272] or SNX2 [MIM
605929]; and SNX5 [MIM 605937] or SNX6 [MIM
606098]). Coimmunoprecipitation analyses of VPS35
p.Pro316Ser and p.Asp620Asn substitutions indicate that
neither is likely to result in aberrant complex formation
(Figure S2). However, VPS35 is known to directly associateerican Journal of Human Genetics 89, 162–167, July 15, 2011 165
with cargos, including soluble N-ethylmaleimide-sensitive
factor attachment protein receptor (SNARE) proteins,
SORL1 [MIM 602005] and SORT1 [MIM 602458], and
MUL1 [MIM 612037].13–15 We hypothesize that mutations
perturb cargo recognition and binding and that this pertur-
bation results in deficient receptor recycling, but such
effects are likely to be subtle given the late onset of disease.
In parkinsonism, alpha-synuclein has been proposed to
regulate SNARE proteins, which are involved in vesicle
fusion and exocytosis,16 whereas leucine-rich repeat kinase
2 (LRRK2 [MIM 609007]) is a central regulator of neuritic
outgrowth, morphology, and cellular homeostasis, in part
through the regulation of endosomal trafficking.17
The identification of VPS35 pathogenic mutations in PD
provides a compelling genetic link for the retromer in
neurodegeneration. In Alzheimer disease [MIM 104300],
retromer deficiency impairs Wnt signaling and amyloid
precursor protein (APP [MIM 104760]) trafficking, and it
is associated with an elevation in endogenous amyloid-
beta peptide.18,19 Nevertheless, dementia is not prominent
in patients with parkinsonism and VPS35 p.Asp620Asn.
Cognitive deficits were observed in two family members
with parkinsonism and VPS35 p.Pro316Ser mutations
(US-2), but assessment of cognitive decline in VPS35muta-
tion carriers requires further evaluation. The recruitment
ofVPS26/29/35 complex to endosomes is initially catalyzed
by RAB7 [MIM 602298].20 This dynamic interaction is per-
turbed by RAB7mutations in Charcot-Marie-Tooth type 2B
neuropathy (CMT2B [MIM 600882]).20,21 The human
genome contains more than 60 RAB proteins that regulate
vesicular transport between cellular compartments and
may provide cell-type specificity. Of note, RAB7L1 [MIM
603949] is adjacent to rs947211 (PARK16), recently nomi-
nated in PD susceptibility through a GWAS.22 Interaction
between dynactin (DCTN1 [MIM 601143]) and SNX6 is
also required for endosome-trans-Golgi transport and
provides another link between retromer function and
parkinsonism in that mutations in DCTN1 have recently
been implicated in Perry syndrome [MIM 168605].23,24
The retromer plays a central and intermediate role in
recycling of membrane-associated proteins and endoso-
mal-lysosomal trafficking. VPS35 mutations provide
a mechanistic tool for exploring dominant-negative versus
toxic gain of function and will allow the generation of
in vitro and in vivo systems that address whether gene
expression or transport of specific cargos explains the selec-
tive vulnerability of dopaminergic neurons. Endosomal
trafficking appears to be a common pathway disrupted in
neurodegenerative diseases. Screening of VPS35 and its in-
teracting partners, not only in PD but also in other move-
ment and cognitive disorders, is warranted if we are to fully
understand the role of the retromer indisease development.Supplemental Data
Supplemental Data include two figures and five tables and can be
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